{"id":25010,"date":"2024-05-27T09:00:09","date_gmt":"2024-05-27T09:00:09","guid":{"rendered":"http:\/\/107416566"},"modified":"2024-05-27T09:00:09","modified_gmt":"2024-05-27T09:00:09","slug":"how-digital-health-companies-are-capitalizing-on-the-glp-1-boom","status":"publish","type":"post","link":"https:\/\/wp.worldtechguide.net\/how-digital-health-companies-are-capitalizing-on-the-glp-1-boom\/","title":{"rendered":"How digital health companies are capitalizing on the GLP-1 boom"},"content":{"rendered":"<p><span class=\"HighlightShare-hidden\"><\/span><\/p>\n<div class=\"InlineImage-imageEmbed\" id=\"ArticleBody-InlineImage-107310826\" data-test=\"InlineImage\">\n<div class=\"InlineImage-wrapper\">\n<div>\n<p>Patent protection for Wegovy \u2014 Novo Nordisk&#8217;s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective \u2014 is expected to expire by the decade&#8217;s end.<\/p>\n<p>Michael Siluk | UCG | Getty Images<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p>For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She&#8217;d tried five different programs in her life and never found lasting results.<\/p>\n<p>Her luck started to change last year, when she saw a promotion on Instagram for the <span class=\"waslinkname\">Ro Body Program<\/span>, a new offering from online health startup Ro. The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that&#8217;s turned into a booming business in recent years.<\/p>\n<p>Beard, 47, had previously sought a GLP-1 prescription, but her doctor &#8220;wouldn&#8217;t even try&#8221; to get it approved, assuming her insurance company would reject coverage of the costly medication, she said. GLP-1s cost roughly $1,000 per month before insurance and other rebates.&nbsp;<\/p>\n<p>Customers of Ro&#8217;s Body Program could get prescribed a GLP-1, such as <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-2\"><span class=\"waslinkname\">Novo Nordisk<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> &#8216;s weight loss drug Wegovy or diabetes treatment Ozempic, and meet monthly with a doctor. They also get access to an educational curriculum, 24\/7 messaging, one-on-one coaching with nurses and assistance with navigating insurance complexities.&nbsp;<\/p>\n<p>Beard was 210 pounds when she first started the program early last year. She&#8217;s since lost 40 pounds and serves as an ambassador for Ro. She pays $30 per month for the GLP-1 treatment, after insurance coverage, along with a $145 monthly fee for the program. And she has no plans to leave.<\/p>\n<p>&#8220;I&#8217;m fine if I have to stay on it forever,&#8221; Beard told CNBC.<\/p>\n<p>Ro, founded as Roman in 2017, is part of a growing crop of digital health companies aiming to capitalize on the <span class=\"waslinkname\">soaring demand for GLP-1s<\/span> by building programs and services for users on top of the medications. The opportunity could be massive. <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-4\"><span class=\"waslinkname\">Goldman Sachs<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, and predict the industry could reach $100 billion in annual revenue by that time.<\/p>\n<p>In addition to Wegovy and Ozempic, the GLP-1 class includes <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-5\"><span class=\"waslinkname\">Eli Lilly&#8217;s<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. GLP-1s mimic a hormone produced in the gut to suppress a person&#8217;s appetite and regulate blood sugar.<\/p>\n<p>Like Ro, other non-drugmakers, including Calibrate, Sesame, Omada Health, Noom, <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-6\"><span class=\"waslinkname\">Hims &amp; Hers<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> and even telehealth industry veterans <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-7\"><span class=\"waslinkname\">Teladoc Health<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> and <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-8\"><span class=\"waslinkname\">WeightWatchers<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span>, have rolled out offerings geared toward patients on GLP-1s, or have expanded their services to include the popular medications. <\/p>\n<p>Meanwhile, investors are cheering them on.<\/p>\n<p>Shares of Ro competitor Hims &amp; Hers popped 28% on May 20 after the company said it&#8217;s now <span class=\"waslinkname\">offering compounded GLP-1 injections<\/span> in addition to its oral medication kits. CEO Andrew Dudum told CNBC the company is confident customers will be able to access a consistent supply of the injections.&nbsp;<\/p>\n<\/div>\n<div role=\"region\" aria-labelledby=\"Placeholder-ArticleBody-Video-107417511\">\n<div role=\"button\" id=\"Placeholder-ArticleBody-Video-107417511\" class=\"PlaceHolder-wrapper\" data-vilynx-id=\"7000340793\" data-test=\"VideoPlaceHolder\">\n<div class=\"InlineVideo-videoEmbed\" id=\"InlineVideo-0\" data-test=\"InlineVideo\">\n<div class=\"InlineVideo-wrapper\">\n<div class=\"InlineVideo-inlineThumbnailContainer\"><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/wp.worldtechguide.net\/wp-content\/uploads\/2024\/05\/how-digital-health-companies-are-capitalizing-on-the-glp-1-boom.jpg\" alt=\"Dr. Craig Primack talks Hims &amp; Hers launching its own GLP-1 offering as demand rises\"><span class=\"InlineVideo-videoButton\"><\/span><span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p>Supply shortages are one of the big hurdles for companies in the market, as spiking demand has made it difficult for many patients to access the treatments. There&#8217;s also been a rise of counterfeit products, according to the World Health Organization, which <span class=\"waslinkname\">said in January<\/span> that the combination of shortages and the &#8220;increased circulation of falsified versions&#8221; is particularly problematic for patients with Type 2 diabetes who count on the medication for disease management.<\/p>\n<p>That&#8217;s not slowing down industry executives like Ro founder Zachariah Reitano.<\/p>\n<p>Ro didn&#8217;t start out as a company focused on weight loss. Reitano launched it to sell treatments online for erectile dysfunction before moving on to hair loss and other pathologies.<\/p>\n<p>In 2020, Ro switched to obesity management and, after Wegovy was approved by the Food and Drug Adminstration the following year, Reitano said patient inquiries started pouring in by the &#8220;tens of thousands.&#8221;<\/p>\n<p>Now, Ro is shoveling marketing dollars into its GLP-1 program \u2014 from digital ads, TV commercials and posters lining subway stations, to influencer campaigns featuring patients such as Beard.&nbsp;<\/p>\n<p>Reitano told CNBC that GLP-1s are like a &#8220;jetpack for positive behavior change.&#8221; Patients tend to exercise more, eat healthier and see around a 30% reduction in calorie intake, he said.<\/p>\n<p>&#8220;Once you get a little bit of momentum, once you lose a little bit of weight, you&#8217;re sleeping better, you have more energy, you can go to the gym, you can eat better and then that&#8217;s that positive flywheel,&#8221; Reitano said.<\/p>\n<p>Ro has raised around <span class=\"waslinkname\">$1 billion<\/span> in funding to date, according to PitchBook. The company was valued at about <span class=\"waslinkname\">$7 billion<\/span> as of early 2022, though that was before a steep drop in tech stocks and <span class=\"waslinkname\">collapse in the initial public offering market<\/span> forced many startups to dramatically lower their valuations.<\/p>\n<\/div>\n<h2 class=\"ArticleBody-subtitle\">WeightWatchers joins the market<\/h2>\n<div class=\"group\">\n<p><span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-14\"><span class=\"waslinkname\">WeightWatchers<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> has been in business for over 60 years and is the name in the U.S. perhaps most synonymous with weight loss programs.<\/p>\n<p>In December, the company entered the GLP-1 market, with a behavioral-support program that&#8217;s available through its general membership subscription, starting at $23 per month. Members can participate whether they get a GLP-1 prescription through their primary care physician or through the new WeightWatchers Clinic, introduced alongside the behavioral program.<\/p>\n<p>Because GLP-1s suppress appetites, WeightWatchers quickly learned that it needed an entirely new program for people taking the meds, said Gary Foster, the company&#8217;s chief scientific officer.<\/p>\n<p>&#8220;They don&#8217;t need help with what to do for dessert or how to deal with the bread on the table at a restaurant,&#8221; Foster said in an interview. &#8220;That&#8217;s like 50-60% of what we would do for people without meds.&#8221;&nbsp;<\/p>\n<p>Clinic members who participate in the GLP-1 program have to pay an additional fee \u2014 starting at $99 a month \u2014 for exclusive access to registered dieticians, fitness professionals and care team coordinators.&nbsp;<\/p>\n<p>WeightWatchers said in its <span class=\"waslinkname\">first-quarter results<\/span> earlier this month that 87,000 people had subscribed to the clinic, although not all of them are taking GLP-1s. The company expects to have between 140,000 and 160,000 clinic subscribers by year-end, the report said.&nbsp;<\/p>\n<p>It hasn&#8217;t been enough to change WeightWatchers&#8217; trajectory. The stock has plummeted 83% this year on concerns about the company&#8217;s debt load, its core weight loss business and Oprah Winfrey&#8217;s <span class=\"waslinkname\">announced departure<\/span> from the board in February.<\/p>\n<p>With respect to GLP-1s and their impact on weight loss, &#8220;the landscape is quite exciting,&#8221; Foster said. &#8220;I think we should all celebrate and really be delighted by the fact that there are more tools in the toolbox to help people trying to manage their weight.&#8221;&nbsp;<\/p>\n<\/div>\n<div class=\"InlineImage-imageEmbed\" id=\"ArticleBody-InlineImage-107392998\" data-test=\"InlineImage\">\n<div class=\"InlineImage-wrapper\">\n<div>\n<p>Kim Gradwell with an Ozempic injection needle at her home in Dudley, North Tyneside, Britain, October 31, 2023.&nbsp;<\/p>\n<p>Lee Smith | Reuters<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p>Jennifer VanGilder, a 51-year-old economics professor at Ursinus College in Collegeville, Pennsylvania, said she&#8217;d tried countless methods to lose weight, from strict diets to services like the <span class=\"waslinkname\">defunct Jenny Craig<\/span>. She was considering bariatric surgery before she came across a program from digital health startup Calibrate.&nbsp;&nbsp;&nbsp;<\/p>\n<p>Calibrate, founded in 2019, was one of the first companies to treat obesity by combining GLP-1s with one-on-one coaching. The program costs $199 a month, which doesn&#8217;t include the medication, and requires an initial three-month-long commitment.<\/p>\n<p>VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. She later switched to Wegovy.&nbsp;<\/p>\n<p>VanGilder said GLP-1s aren&#8217;t a miracle drug, but by taking them and putting in the work, she said she lost around 100 pounds of her 242-pound weight. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn&#8217;t feel like she&#8217;s dieting.<\/p>\n<p>&#8220;That&#8217;s why I&#8217;ve been able to stay on it for as long as I have,&#8221; VanGilder said.<\/p>\n<p>Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The company&#8217;s<span class=\"waslinkname\"> 2024 report<\/span> examined data from roughly 16,000 members who completed at least one year of the program as of October, along with a smaller group of patients who continued for longer.&nbsp;<\/p>\n<p>Average weight loss among patients was 16.2% at 12 months in the program, 17.3% at 18 months and 17.9% at 24 months, according to the report.&nbsp;<\/p>\n<p>&#8220;Our data of proven outcomes shows that we can deliver faster, better results than some of the leading GLP-1 clinical trials,&#8221; said Dr. Kristin Baier, Calibrate&#8217;s vice president of clinical development, in an interview.<\/p>\n<p>But Calibrate has hit some major speed bumps in the past couple years.<\/p>\n<p>After <span class=\"waslinkname\">raising $100 million<\/span> in venture funding during the peak of the tech market in 2021, the combination of supply shortages, insurance challenges and the broader market swoon forced the startup to <span class=\"waslinkname\">lay off hundreds of employees<\/span> between 2022 and 2023. The company was <span class=\"waslinkname\">acquired<\/span> in October at a discount by private equity firm Madryn Asset Management.<\/p>\n<p>Calibrate CEO Rob MacNaughton said the sector was &#8220;ill equipped&#8221; to manage the &#8220;dramatic demand that led to, at some point, severely, severely constrained supply&#8221; of GLP-1s last year.&nbsp;<\/p>\n<p>Under new ownership, the company continues to promote its GLP-1 service, which its said is important because the drugs themselves aren&#8217;t sufficient.<\/p>\n<p>&#8220;GLP-1 medications, while they are safe and effective, they are a tool,&#8221; said Baier. &#8220;They are not the entire treatment.&#8221;<\/p>\n<\/div>\n<h2 class=\"ArticleBody-subtitle\">Options for patients<\/h2>\n<div class=\"group\">\n<p>Ro&#8217;s Reitano said shortages of Wegovy and other GLP-1s last year prompted his company to temporarily pause advertising. Ro also dolled out refunds and credits to patients in its program who weren&#8217;t able to pick up their medication within 30 days of receiving a prescription, he said.&nbsp;<\/p>\n<p>Reitano said Ro has built up &#8220;both technical tools and operations&#8221; to help patients navigate supply issues. That includes transferring prescriptions to different pharmacies based on their GLP-1 supply and proximity to a patient. From July to August, the company made 50,000 phone calls to pharmacies across the U.S. to coordinate those transfers, Reitano said.&nbsp;<\/p>\n<p>Ro has also expanded its medication offerings, adding Zepbound following its U.S. approval in November.&nbsp;<\/p>\n<p>&#8220;We added that to our formulary, and that&#8217;s really when we started advertising again because we had confidence that we&#8217;d be able to get patients an option,&#8221; Reitano said.&nbsp;<\/p>\n<\/div>\n<div role=\"region\" aria-labelledby=\"Placeholder-ArticleBody-Video-107351952\">\n<div role=\"button\" id=\"Placeholder-ArticleBody-Video-107351952\" class=\"PlaceHolder-wrapper\" data-vilynx-id=\"7000326913\" data-test=\"VideoPlaceHolder\">\n<div class=\"InlineVideo-videoEmbed\" id=\"InlineVideo-0\" data-test=\"InlineVideo\">\n<div class=\"InlineVideo-wrapper\">\n<div class=\"InlineVideo-inlineThumbnailContainer\"><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/wp.worldtechguide.net\/wp-content\/uploads\/2024\/05\/how-digital-health-companies-are-capitalizing-on-the-glp-1-boom-1.jpg\" alt=\"Ro CEO on telehealth and the impact of weight loss drugs\"><span class=\"InlineVideo-videoButton\"><\/span><span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p>Insurance problems persist, though.<\/p>\n<p>Some employers have dropped weight loss drugs from their plans due to the costs associated with covering the treatments for thousands of patients. The federal Medicare program by law can&#8217;t cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health.&nbsp;<\/p>\n<p>Eli Lilly and <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-22\"><span class=\"waslinkname\">Novo Nordisk<\/span><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"><\/span><\/button><\/span><\/span><\/span> offer commercial savings card programs that aim to expand access to their GLP-1s. Eli Lilly <span class=\"waslinkname\">allows<\/span> people with insurance coverage for Zepbound to pay as low as $25 for a monthly prescription. And users who can&#8217;t get insurance coverage, may be able to get the drug for as low as $550 a month.<\/p>\n<p>The high costs and difficult access led Hims &amp; Hers to initially stay out of the GLP-1 market even after <span class=\"waslinkname\">launching<\/span> its new weight loss program in December<\/p>\n<p>Dr. Craig Primack, senior vice president of weight management at Hims, said the company decided to offer treatment regimens based on drugs that had been studied and prescribed for decades.&nbsp;&nbsp;<\/p>\n<p>&#8220;We&#8217;re going to have people, for one reason or another, who either don&#8217;t want an injection at this point, or are just looking for a different alternative,&#8221; Primack told CNBC in an interview in March. &#8220;These are tools we&#8217;ve been using in our field for a long, long time.&#8221;<\/p>\n<p>Last week, Hims said customers can now access compounded GLP-1 medications via a prescription from a licensed health-care provider on the platform. Hims said it plans to make branded GLP-1 medications available to its customers once supply is consistently available. The company&#8217;s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.<\/p>\n<p>Dudum said the company has partnered with one of the largest generic manufacturers in the U.S. and has a certain degree of exclusivity with the facility. The manufacturer has FDA oversight, he said.&nbsp;<\/p>\n<p>Even before Hims introduced compounded GLP-1 injections to its weight loss offering, the company <span class=\"waslinkname\">said<\/span> it expects the program will generate more than $100 million in revenue by the end of 2025.<\/p>\n<p>Beard, the Ro customer, has had to make some changes since starting the Body Program. She initially took Wegovy with no out-of-pocket costs, thanks to her insurance coverage and a savings card program from Novo Nordisk. But she hit a plateau on the drug, so she switched to Zepbound.&nbsp;<\/p>\n<p>While there have been some hiccups along the way, Beard says the program has largely been a &#8220;seamless&#8221; addition to her day-to-day life, and that she no longer thinks about food all the time. She even got a family member to enroll.<\/p>\n<p>&#8220;We&#8217;re not having any bad side effects, so why go off of it?&#8221; she said, adding &#8220;it&#8217;s helped both of us get to the weight we want.&#8221;<\/p>\n<\/div>\n<div class=\"group\">\n<div class=\"RelatedContent-relatedContent\" id=\"RegularArticle-RelatedContent-1\">\n<div class=\"RelatedContent-container\">\n<div class=\"RelatedContent-nonCollapsibleContent\">\n<h2 class=\"RelatedContent-header\">Don\u2019t miss these exclusives from CNBC PRO<\/h2>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div role=\"region\" aria-labelledby=\"Placeholder-ArticleBody-Video-107390453\">\n<div role=\"button\" id=\"Placeholder-ArticleBody-Video-107390453\" class=\"PlaceHolder-wrapper\" data-vilynx-id=\"7000334997\" data-test=\"VideoPlaceHolder\">\n<div class=\"InlineVideo-videoEmbed\" id=\"InlineVideo-0\" data-test=\"InlineVideo\">\n<div class=\"InlineVideo-wrapper\">\n<div class=\"InlineVideo-inlineThumbnailContainer\"><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/wp.worldtechguide.net\/wp-content\/uploads\/2024\/05\/how-digital-health-companies-are-capitalizing-on-the-glp-1-boom-2.jpg\" alt=\"Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan Seigerman\"><span class=\"InlineVideo-videoButton\"><\/span><span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Patent protection for Wegovy \u2014 Novo Nordisk&#8217;s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective \u2014 is expected to expire by the decade&#8217;s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had &hellip;<\/p>\n","protected":false},"author":1,"featured_media":25011,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"hashtags":[],"class_list":["post-25010","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech","has-thumb","has-featured"],"_links":{"self":[{"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/posts\/25010"}],"collection":[{"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/comments?post=25010"}],"version-history":[{"count":0,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/posts\/25010\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/media\/25011"}],"wp:attachment":[{"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/media?parent=25010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/categories?post=25010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/tags?post=25010"},{"taxonomy":"hashtags","embeddable":true,"href":"https:\/\/wp.worldtechguide.net\/wp-json\/wp\/v2\/hashtags?post=25010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}